Tag

Hiv Treatment

All articles tagged with #hiv treatment

health1 month ago•3 min saved

FDA Approves Gilead’s Bixlenvo to Simplify Regimens for Suppressed HIV Patients

The FDA has approved Bixlenvo, a once-daily single-tablet regimen from Gilead Sciences for adults with HIV whose virus is already suppressed. Combining bictegravir and lenacapavir, the drug targets patients unable to use existing one-pill options due to resistance or side effects. Priced at $4,595 per month, it offers a simplified alternative for those managing complex multi-drug regimens, with trials showing maintained viral suppression and no new safety concerns.

via CNBC|

#bixlenvo #fda-approval #gilead-sciences

health2 months ago

Weekly HIV Regimens Show Promise, but Stigma and Resistance Gaps Remain

New data from the International AIDS Conference in Rio de Janeiro highlights the potential of once-weekly oral antiretroviral therapy (ART) to improve adherence and reduce stigma. While trials show comparable viral suppression to daily dosing, experts emphasize that stigma persists and long-term safety data is still being gathered.

via standardmedia.co.ke|

#aids-2026 #antiretroviral-therapy #clinical-trials

health2 months ago•2 min saved

Weekly HIV Pill Trial Shows Equal Efficacy to Daily Dose

An international clinical trial confirms that a once-weekly oral antiretroviral therapy (ART) regimen is as effective as daily medication for suppressing HIV. The study, involving 607 participants across 12 countries, found that the combination of islatravir and lenacapavir maintained viral suppression rates comparable to standard daily treatments. While this offers a significant alternative to daily pills and semi-annual injections, experts note that stigma remains a major barrier for people living with HIV.

via BBC|

#antiretroviral-therapy #clinical-trials #health

health2 months ago•5 min saved

VH-499 Capsid Inhibitor Shows Potent Viral Suppression in Early HIV Trial

A new oral HIV drug, VH-499, demonstrated potent antiviral activity and a favorable safety profile in a phase 2a trial involving 23 adults. The drug, developed by ViiV Healthcare, works by inhibiting the viral capsid and avoids interfering with the CYP3A4 enzyme, potentially offering advantages for patients with complex medication regimens compared to existing long-acting therapies like lenacapavir.

via ScienceAlert|

#antiretroviral-therapy #capsid-inhibitors #clinical-trials

law1 year ago•3 min saved

Lawsuit Challenges Idaho's Immigration Benefits Restrictions

A lawsuit filed by the ACLU of Idaho challenges a new state law that restricts public benefits for undocumented immigrants, including access to HIV/AIDS medication, citing vagueness and conflict with federal law, and raising concerns about public health and patient care. The law, set to take effect on July 1, limits benefits requiring verification of lawful U.S. residency, impacting vulnerable populations and healthcare providers.

via CBS News|

#hiv-treatment #idaho-law #law

health1 year ago•1 min saved

Report: Unsupported Drug Price Hikes Cost U.S. $815M in 2023

In 2023, drugmakers increased prices on five widely used drugs without new clinical evidence, costing U.S. patients and insurers an additional $815 million, according to a report by the Institute for Clinical and Economic Review. The largest spending increase was for Biktarvy, an HIV treatment by Gilead Sciences, which saw a 5.9% wholesale price hike, resulting in $359 million more in spending. Gilead claims some study data were overlooked or rejected, challenging the report's findings.

via STAT|

#drug-pricing #gilead-sciences #health

business2 years ago•33 min saved

"Gilead Sciences: Navigating Financial Results, Cell Therapy Movement, and COVID Drug Trials"

Gilead Sciences reported a 7% increase in product sales excluding Veklury for the full year 2023, with Biktarvy sales up 14% and oncology sales up 37%. However, total fourth quarter 2023 revenue decreased by 4% to $7.1 billion compared to the same period in 2022, primarily due to lower Veklury and HIV sales, partially offset by higher oncology sales. The company also provided guidance for full-year 2024, expecting total product sales between $27.1 billion and $27.5 billion and diluted EPS between $5.15 and $5.55.

via Gilead Sciences|

#business #financial-results #gilead-sciences

health3 years ago•3 min saved

"Promising Medical Breakthrough Advances HIV Cure Research"

Researchers at Tokyo Medical and Dental University have made a significant breakthrough in the treatment of HIV-1, the virus responsible for AIDS. They have identified a compound called YSE028 that can activate latent HIV-1 in cells, potentially leading to more effective HIV treatments and even a cure. The compound activates a protein called protein kinase C (PKC) without causing significant toxicity to cells. Further research and clinical trials are needed to fully understand the implications and effectiveness of this compound in future HIV treatments.

via Study Finds|

#cure #health #hiv